Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $787.67 Average Target Price from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received an average recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $787.6667.

A number of research firms have recently commented on REGN. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Finally, Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms announced or promoted securities class-action activity tied to REGN, including a newly filed class action and related investor deadline notices. These developments can weigh on sentiment because they highlight alleged disclosure issues and raise the risk of legal costs or settlement uncertainty. Article: Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
• Negative Sentiment: Additional reminders from Faruqi & Faruqi, Robbins LLP, Levi & Korsinsky, and Bragar Eagel & Squire kept the lawsuit story in focus, reinforcing legal overhang for shareholders. Article: REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.
• Neutral Sentiment: A market commentary piece said Regeneron has rebounded and may still look undervalued, but also questioned whether the upside is already reflected in the shares, making the stock’s near-term direction less clear. Article: Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
• Neutral Sentiment: Brokerage coverage cited by American Banking News said REGN carries a “Moderate Buy” consensus, which supports the long-term outlook but is less likely to move the stock immediately than the litigation headlines. Article: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in REGN. Brighton Jones LLC raised its position in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals in the first quarter worth $226,000. Arrowstreet Capital Limited Partnership purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $3,183,000. Gabelli Funds LLC increased its stake in Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares during the last quarter. Finally, Sei Investments Co. increased its stake in Regeneron Pharmaceuticals by 18.8% in the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after acquiring an additional 5,120 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $676.69 on Friday. The stock has a 50 day moving average of $640.99 and a 200 day moving average of $717.97. The company has a market capitalization of $71.54 billion, a price-to-earnings ratio of 16.49, a PEG ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.22 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.